@article{5d1730499ebe4630a57d1d2efdc36128,
title = "Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses",
abstract = "Messenger RNA (mRNA) vaccines represent a new, effective vaccine platform with high capacity for rapid development. Generation of a universal influenza virus vaccine with the potential to elicit long-lasting, broadly cross-reactive immune responses is a necessity for reducing influenza-associated morbidity and mortality. Here we focus on the development of a universal influenza B virus vaccine based on the lipid nanoparticle-encapsulated nucleoside-modified mRNA (mRNA-LNP) platform. We evaluate vaccine candidates based on different target antigens that afford protection against challenge with ancestral and recent influenza B viruses from both antigenic lineages. A pentavalent vaccine combining all tested antigens protects mice from morbidity at a very low dose of 50 ng per antigen after a single vaccination. These findings support the further advancement of nucleoside-modified mRNA-LNPs expressing multiple conserved antigens as universal influenza virus vaccine candidates.",
author = "Norbert Pardi and Carre{\~n}o, {Juan Manuel} and George O{\textquoteright}Dell and Jessica Tan and Csaba Bajusz and Hiromi Muramatsu and Willemijn Rijnink and Shirin Strohmeier and Madhumathi Loganathan and Dominika Bielak and Sung, {Molly M.H.} and Tam, {Ying K.} and Florian Krammer and Meagan McMahon",
note = "Funding Information: The study was partially supported by NIH R01-AI146101 (N.P. and M.M.) and by the Collaborative Influenza Vaccine Innovation Centers (CIVICs) contract 75N93019C00051 (F.K.). We thank the Mount Sinai Pathogen Surveillance Program, and especially Viviana Simon and Harm van Bakel, for sharing influenza virus isolates B/New York City/PV00094/2017 and B/New York City/PV01181/2018. The overlapping peptide pools used in the T cell studies were kindly provided by Michael J. Hogan and Laurence C. Eisenlohr (CHOP). Figure was created with BioRender. Funding Information: The study was partially supported by NIH R01-AI146101 (N.P. and M.M.) and by the Collaborative Influenza Vaccine Innovation Centers (CIVICs) contract 75N93019C00051 (F.K.). We thank the Mount Sinai Pathogen Surveillance Program, and especially Viviana Simon and Harm van Bakel, for sharing influenza virus isolates B/New York City/PV00094/2017 and B/New York City/PV01181/2018. The overlapping peptide pools used in the T cell studies were kindly provided by Michael J. Hogan and Laurence C. Eisenlohr (CHOP). Figure 5a was created with BioRender. Publisher Copyright: {\textcopyright} 2022, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.",
year = "2022",
month = dec,
doi = "10.1038/s41467-022-32149-8",
language = "English",
volume = "13",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",
}